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Abstract
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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder in the world, and
intracellular neurofibrillary tangles and extracellular amyloid-beta protein deposits represent the
major pathological hallmarks of the disease. Currently available treatments provide some
symptomatic relief but fail to modify primary pathological processes that underlie the disease.
Erythropoietin (EPO), a hematopoietic growth factor, acts primarily to stimulate erythroid cell
production, and is clinically used to treat anemia. EPO has evolved as a therapeutic agent for
neurodegeneration and has improved neurological outcomes and AD pathology in rodents.
However, penetration of the blood-brain barrier (BBB) and negative hematopoietic effects are the
two major challenges for the therapeutic development of EPO for chronic neurodegenerative
diseases like AD. The transferrin receptors at the BBB, which are responsible for transporting
transferrin-bound iron from the blood into the brain parenchyma, can be used to shuttle therapeutic
molecules across the BBB. In this review, we discuss the role of EPO as a potential
neurotherapeutic for AD, challenges associated with EPO development for AD, and targeting the
BBB transferrin receptor for EPO brain delivery.
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(I) Pathological mechanisms and recent insights of Alzheimer’s disease
Alzheimer’s disease (AD), a neurodegenerative disorder accounting for more than 60% of
the 36.5 million dementia cases worldwide, is characterized by progressive memory loss,
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cognitive decline, and an inability to complete daily tasks such as driving, housekeeping, and
keeping track of finances (Sosa-Ortiz et al. 2012). In 2017, the average cost of health care
and long-term care for a patient with AD was $48,000/year. Furthermore, care provided by
family members and unpaid caregivers was estimated at $232 billion (2018 Alzheimer’s
disease facts and figures 2018). Since AD incidence in individuals ≥85 years old is expected
to increase from 40% in 2001 to 62% in 2050 with the aging of the baby boomer population,
the disease burden of AD in coming years will be immense (Hebert et al. 2001).
During early stages of AD, patients may exhibit either anosognosia, an inability to perceive
their illness, or simply ignore their symptoms, attributing their memory loss to normal aging
(Barrett et al. 2005). These factors greatly contribute to the delay in diagnosis and the
underestimation of disease incidence and prevalence.

Author Manuscript

As the disease progresses, memory impairment is followed by motor and visuospatial
deficits, with patients experiencing extrapyramidal symptoms, apraxia or seizures (Portet et
al. 2009; Giannakopoulos et al. 1998; Vossel et al. 2017). In late-stage AD, patients may
become disinhibited, withdrawn or mute, therefore requiring daily supervision while eating,
dressing, and bathing (Sarazin et al. 2005). These patients begin to rely heavily on
caregivers, leading to an increased incidence of caregiver burnout (Dauphinot et al. 2015).
This burnout often persists for years, as the median time from diagnosis to death in AD
patients is 3.8 years, with many dying of malnutrition or infection (James et al. 2014;
Mitchell et al. 2009). Some patients may live with the disease much longer, causing a strain
on financial and societal resources for decades.

Pathogenesis
Author Manuscript

Many hypotheses have been developed to elucidate AD pathogenesis; however, the amyloid
cascade, cholinergic, and inflammatory hypotheses remain among the most heavily studied
(J. Hardy 2009; De Felice et al. 2008; Eikelenboom et al. 2006; Bartus et al. 1982). An
infectious origin of the disease has also gained traction in recent years (Mawanda and
Wallace 2013).
The Amyloid Cascade Hypothesis

Author Manuscript

The leading model for AD progression is the amyloid cascade hypothesis, which posits that
the deposition of β-amyloid (Aβ) is the initial pathological event in AD leading to the
formation of senile plaques followed by neurofibrillary tangles (NFT). This leads to
downstream neuronal cell death and ultimately dementia due to central nervous system
(CNS) dysfunction (J. A. Hardy and Higgins 1992). Aβ is a protein consisting of 38–43
amino acids; it is formed proteolytically when amyloid precursor protein (APP) is cleaved
by β- and γ-secretases via the amyloidogenic pathway (Haass and De Strooper 1999; Chow
et al. 2010; Gremer et al. 2017). The role of APP in synaptic transmission helps explain its
endogenous abundance within the brain (Priller et al. 2006). Two forms of Aβ that are
abundantly found in the AD brain are Aβ40 and Aβ42, the latter being more abundant and
exhibiting greater CNS toxicity (Potter et al. 2013; Wildburger et al. 2017). As Aβ
accumulates within the brain, it forms insoluble neuritic plaques, which contain a central
amyloid core surrounded by activated microglia (Hong et al. 2016). Furthermore, Aβ plaque
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accumulation induces hyperphosphorylation of tau protein resulting in further toxicity to the
CNS (De Felice et al. 2008). Hyperphosphorylated tau is unable to bind and stabilize
microtubules, and instead aggregates to form NFT, leading to downstream synaptic loss and
impaired neuroregeneration (Z. Zhang et al. 2014). In concurrence with their involvement in
AD pathology, Aβ and tau are often measured in the cerebrospinal fluid of patients for
disease staging and prognostication (Braak et al. 2006; Thal et al. 2002), and a lot of
research efforts are focused on reducing the burden of Aβ and NFT aggregation in the brain
to stop AD progression (Panza et al. 2012).
Neurotransmitter Dysfunction and Synaptic Loss

Author Manuscript
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Aβ and NFT disrupt normal synaptic transmission to neighboring cerebral areas (DeKosky
and Scheff 1990). Neurotransmitters are often seen in abnormal amounts in AD patients
(Lombardo and Maskos 2015; Wenk 2003; Kandimalla and Reddy 2017). For example,
choline acetyltransferase, which is involved in the synthesis of acetylcholine, one of the
most studied neurotransmitters in AD pathogenesis, is decreased in post-mortem AD brains
(Slotkin et al. 1990). The excitatory neurotransmitter, glutamate, accumulates in AD brains,
leading to increased N-methyl-D-aspartate (NMDA) receptor activation (Revett et al. 2013)
and Aβ plaque formation (Dinamarca et al. 2012). Furthermore, Aβ plaque formation
weakens synaptic inhibition via downregulation of gamma-Aminobutyric acid receptors,
causing increased excitotoxicity in the CNS (Ulrich 2015). Serotonin receptors, which are
involved in cognitive processing, are also downregulated in the cortical and hippocampal
areas, contributing to cognitive decline in AD brains (Reynolds et al. 1995). Histamine,
another neurotransmitter important in cognitive functioning, also plays a crucial role in the
pathogenesis of AD (Kandimalla and Reddy 2017). Overall, improper synaptic
communication has been linked to an imbalance in neurotransmitter levels, causing
downstream synaptic loss and cognitive decline. Thus, drugs that work to replenish normal
neurotransmitter levels have been developed for AD (Reisberg et al. 2003; Bartus et al.
1982).
Mitochondrial Dysfunction and Oxidative Stress
Mitochondrial dysfunction, a naturally occurring part of the aging process, is an early
finding in AD pathogenesis. Aβ and tau aggregates impair mitochondrial function, causing
oxidative stress within the cell that results in free radical damage (Eckert et al. 2012). This
oxidative stress induces further Aβ accumulation and tau phosphorylation, causing a selfperpetuating cycle of mitochondrial dysfunction, oxidative damage, and plaque formation
(Leuner et al. 2012; Melov et al. 2007).

Author Manuscript

Microglial Activation and Inflammation
The role of neuroinflammation in AD pathogenesis is now widely recognized. In the CNS,
microglia are involved in synaptic remodeling and tissue surveillance. However, pathologic
stimuli, including Aβ plaque accumulation, can result in sustained microglial activation, and
in the AD brain, Aβ plaques and NFT are often found surrounded by activated microglia
(Wang et al. 2015). Activated microglia are involved in Aβ plaque clearance; however,
sustained microglial activation can perturb this clearance process. Activated microglia
secrete pro-inflammatory cytokines like tumor necrosis factor α (TNF-α), and chemokines
Neuromolecular Med. Author manuscript; available in PMC 2020 March 01.
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that further propagate an inflammatory response and neuronal degeneration in AD (Fan et al.
2015; Rogers et al. 1996; Heneka et al. 2015). Astrocytes, T-cells, complement proteins, and
other acute phase reactants are also recruited to the sites of inflammation, causing an
inflammatory storm that results in tissue damage. Moreover, widespread inflammation
encourages free radical formation, inciting further damage (McGeer and McGeer 2003).
Besides accelerating the progression of AD, growing evidence shows that inflammatory
processes may drive AD pathology, thus providing a long window of opportunity for
therapeutic intervention (Wyss-Coray 2006). Therapeutic strategies to mitigate
neuroinflammation in AD, including the development of nonsteroidal anti-inflammatory
drugs, peroxisome proliferator-activated receptor (PPAR)-γ agonists and cytokine inhibitors
have been/or are under investigation (Ardura-Fabregat et al. 2017).

Genetic Risk Factors
Author Manuscript
Author Manuscript

Many genes play a role in the development of AD; however, the most heavily associated is
the gene encoding apolipoprotein-E (Apo-E), a protein involved in cholesterol transport
(Castellano et al. 2011). The Apo-E ε4 allele contributes to poor Aβ clearance from the
brain and is a strong genetic risk factor for late-onset, sporadic AD. On the other hand, the
Apo-E ε2 allele confers AD protective effects and is associated with increased age at onset
(Castellano et al. 2011). Apart from Apo-E, increased APP expression greatly contributes to
disease progression. Encoded by a gene on chromosome 21q21.3–22.05, higher levels of
APP cause familial early-onset AD in patients with Down syndrome, owing to their extra
copy of chromosome 21 (Schupf et al. 1998). Lastly, mutations in the genes encoding
presenilins, neuronal proteins widely expressed in the CNS, are also associated with familial
early-onset AD. Presenilin 1 and presenilin 2 found on chromosome 14q24.3 and 1q31–42
respectively, are critical components of the ɣ-secretase complex and are involved in the
amyloidogenic cleavage of APP (Brunkan and Goate 2005; Rogaev et al. 1995). Other
emerging genes associated with AD risk include genes involved in synapse turnover,
clathrin-mediated endocytosis, amyloid clearance, and inflammation cascades (Karch and
Goate 2015).

Current Treatment Options

Author Manuscript

Currently, there is no pharmacologic cure for AD, and drugs are prescribed to enhance
cognition and treat AD symptoms. FDA-approved drugs for AD belong to two classes:
acetylcholinesterase inhibitors and NMDA receptor antagonists. Acetylcholinesterase
inhibitors currently approved for AD are donepezil, rivastigmine, and galantamine. These
drugs act by increasing the amount of acetylcholine in the brain to reestablish proper
synaptic communication (Bartus et al. 1982). However, these drugs only perform with
modest efficacy and are approved for mild-to-moderate AD. The NMDA receptor antagonist
memantine, on the other hand, works by blocking NMDA receptors to regulate
glutamatergic neurotransmission and prevent synaptic loss, which is thought to improve
cognition in AD (Danysz et al. 2000). AD patients taking memantine show improved
functioning and decreased rate of decline upon cognition testing (van Marum 2009).
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Apart from symptomatic treatment for AD, there are a number of anti-Aβ and anti-tau
therapies in different stages of clinical development (Bachurin et al. 2017). AN1792 was the
first active immunotherapy against Aβ42, however was discontinued due to reports of
meningoencephalitis (Nicoll et al. 2003). Passive forms of immunotherapy against Aβ,
including bapineuzumab and solanezumab, which act on soluble Aβ, performed poorly in
Phase III clinical trials (Panza et al. 2014). Other anti-Aβ agents under development include
antibodies that target aggregated Aβ, including aducanumab and gantenerumab.
Aducanumab slowed cognitive decline and reduced Aβ plaques in patients with early-stage
AD, and is currently being tested in Phase III trials of early-onset AD. Gantenerumab is
currently in phase III trials for prodromal AD.

Author Manuscript

Additionally, β- and γ-secretase inhibitors that prevent the cleavage of APP to pathogenic
Aβ, like verubecestat and semagacestat, have been investigated to reduce the burden of Aβ
plaques in the brain; however, clinical trials were largely unsuccessful (Wan et al. 2009;
Doody et al. 2013). Meanwhile, tau-based immunotherapies are currently in early stages of
clinical development. RG7345, which is a humanized monoclonal antibody targeting the tau
phosphoepitope pS422, caused an improvement in a transgenic mouse AD model but was
discontinued after Phase I clinical trials (Collin et al. 2014; Sigurdsson 2018). Besides these
approaches, drug candidates that target different neuronal receptors (e.g. serotonin receptor
ligands), enzyme inhibitors (e.g. lipoprotein-associated phospholipase A2 inhibitor),
neurotrophic drugs, and anti-inflammatory (e.g. etanercept) approaches, are currently under
development (Bachurin et al. 2017).

(II) Erythropoietin and AD
Author Manuscript

Erythropoietin (EPO), a 30.4 kDa hematopoietic growth factor produced in the kidney, acts
primarily to stimulate erythroid cell production by supporting the survival, proliferation and
differentiation of erythroid progenitor cells (Jelkmann 2013). Recombinant human EPO is
FDA approved and clinically used to treat anemia (Ng et al. 2003). In the past decade, over
60 studies have demonstrated the neuroprotective role of EPO in neurodegenerative
conditions (Jelkmann 2005). As shown in Figure 1, EPO improves neurological outcome in
experimental AD by reducing Aβ load, inflammation, oxidative stress, apoptosis and
neuronal loss (Sargin et al. 2010). Overall, EPO has evolved as a therapeutic agent for CNS
disorders given its robust non-hematopoietic neuroprotective effects.

Expression of EPO and EPO receptor in the CNS
Author Manuscript

The EPO receptor (EPOR) is a highly conserved member of the cytokine receptor
superfamily. EPOR expression in the brain is observed during development and adulthood in
humans and other mammals (Marti et al. 1996). EPO expression is detected in neurons,
astrocytes and pericytes, while EPOR is expressed in neurons, astrocytes and microglia (Ji
2016; Nagai et al. 2001). EPOR is prominently expressed in astrocytes, oligodendrocytes
and certain neuronal populations in fetal brain during gestation (Jelkmann 2005), and brain
EPOR expression is significantly reduced with development, indicating the vital role of EPO
in brain maturation (Juul et al. 1998).

Neuromolecular Med. Author manuscript; available in PMC 2020 March 01.

Sun et al.

Page 6

Author Manuscript

The expression of EPO and EPOR is controlled by hypoxia inducible factor-1 (HIF-1). This
hypoxia-dependent transcription of EPO is regulated via the hypoxia response element in the
3’-flanking region of EPO gene that specifically binds to HIF-1 under hypoxic conditions
(Haase 2013). Neuronal production of EPO is related to the oxygen tension of the medium
in vitro, which is enhanced by hypoxia (Masuda et al. 1994). Further, astrocytic EPO
expression is increased by more than 100-fold under hypoxic conditions (Marti et al. 1996).
Radio-iodinated EPO studies in rats indicate that EPOR expression is localized to the
hippocampal and cortical areas, which are most vulnerable to AD pathology and ischemic
insult (Digicaylioglu et al. 1995). EPOR expression is also observed on the endothelial cells
forming the blood-brain barrier (BBB), and EPOR is upregulated in the temporal cortex and
hippocampus of patients with mild cognitive impairment and AD (Cornford and Hyman
2005; Assaraf et al. 2007).

Author Manuscript

Effect of EPO on AD pathology
Amyloid Toxicity

Author Manuscript

AD is pathologically characterized by the accumulation of Aβ and tau hyperphosphorylation
in the hippocampus and cortex. Therefore, it is important for therapeutic AD agents to act on
toxic Aβ buildup, association of newly cleaved Aβ fragments into oligomers and plaques,
and tau phosphorylation. Intraperitoneal injections of EPO induce a 20% reduction of total
Aβ load and a 59% reduction of Aβ40 protein level in mice; however, no significant decrease
in Aβ42 load is observed after EPO treatment (Armand-Ugon et al. 2015). Tg2576 mice also
exhibit a reduced amount of amyloid plaque after daily intraperitoneal injection of EPO for
5 days (S. T. Lee et al. 2012). Similarly, EPO reduces hippocampal Aβ accumulation in an
intracerebroventricular streptozotocin-induced AD rat model (Samy et al. 2016). Intranasaladministration of EPO also decreases Aβ deposits in an APP/PS1 transgenic AD mouse
model (Rodriguez Cruz et al. 2017). In vitro, EPO is reported to attenuate Aβ25–35-induced
rat pheochromocytoma cell death by regulating anti-apoptotic protein expression (Ma et al.
2009). Further, EPO protects microglia mediated neuronal regeneration and Aβ clearance, in
vitro (Shang et al. 2012). A recent study reported that EPO alleviates tau
hyperphosphorylation via regulation of glycosynthase kinase-3β in a rodent AD model (Y. P.
Li et al. 2015).
Mitochondrial Dysfunction and Oxidative Stress

Author Manuscript

Oxidative stress is linked to mitochondrial dysfunction in AD (Eckert et al. 2012), and EPO
relieves oxidative stress by preventing the accumulation of lipid peroxidation in the
hippocampus of AD mice (Maurice et al. 2013). In vitro, EPO treatment prior to Aβ25–35
exposure significantly elevates cell viability, decreases ROS production, and stabilizes
mitochondrial membrane potential (G. Li et al. 2008). EPO further attenuates nitric oxide
and staurosporine-induced oxidative toxicity in neonatal rat astrocytes by promoting the
expression of heme oxygenase-1 (Diaz et al. 2005), and EPO mediated anti-oxidant effects
reduce neuronal damage by activated microglia (Wenker et al. 2013).
A massive release of synaptic glutamate in brain regions susceptible to Aβ-toxicity leads to
excitotoxicity and oxidative stress, resulting in neurotoxicity. EPO prevents glutamate-

Neuromolecular Med. Author manuscript; available in PMC 2020 March 01.

Sun et al.

Page 7

Author Manuscript

induced excitotoxicity and cell death by inhibiting mitochondrial calcium overload in
cultured rat neurons (Morishita et al. 1997). EPO activates several kinase cascades to confer
resistance against oxidative stress-induced apoptosis (G. Li et al. 2008). It has also been
demonstrated that EPO inhibits Bax/Bcl complex-mediated apoptosis induced by Aβ
(Rodriguez Cruz et al. 2017; Y. P. Li et al. 2015).
Neurotrophic Effects

Author Manuscript

The role of EPO as a neurotrophin and in neurogenesis has been well documented.
Intracerebroventricular administration of EPO significantly increases brain-derived
neurotrophic factor (BDNF) expression in the brain. EPO also induces BDNF production
and long-term activation of its specific receptor, tyrosine receptor kinase B, resulting in EPO
mediated neuroprotection against neurotoxin trimethyltin (Viviani et al. 2005). Notably,
BDNF levels are reduced in AD, and exogenous BDNF offers protection against Aβ- and
tau-related neurodegeneration (Jiao et al. 2016). The role of EPO-derived BDNF in AD,
however, needs further investigation.

Author Manuscript

EPO augments choline acetyltransferase activity in mouse embryonic primary septal neurons
and a cholinergic hybridoma cell line. Moreover, EPO promotes survival of septal
cholinergic neurons in adult rats which have undergone fimbria-fornix transections (Konishi
et al. 1993). Intraperitoneal administration of EPO spurs significant neurogenesis in the
dentate gyrus in the streptozotocin-induced AD rat model; however, EPO does not change
neurogenesis in the dentate gyrus of intact animals (Arabpoor et al. 2012). Tg2576 mice
treated with EPO show increased hippocampal and cortical neurogenesis identified by 5bromo-2-deoxyuridine fluorescent labeling, and increased synaptophysin expression.
Further, EPO enhances endothelial proliferation in the brains of Tg2576 mice, indicating the
positive role of EPO in angiogenesis (S. T. Lee et al. 2012). Overall, these studies indicate
that EPO acts as a potent neurotrophic factor to influence differentiation, maintenance and
regeneration in the CNS.
Neuroinflammation

Author Manuscript

Increasing evidence suggests that neuroinflammation in AD is implicated as a significant
contributor to disease pathogenesis and progression. With respect to neuroinflammation,
EPO prevents the Aβ25–35-induced increase in TNF-α and interleukin (IL) production in a
rodent AD model (Maurice et al. 2013). Besides its effect in AD rodent models, EPO has
been reported to decrease production of TNF-α, IL-6, and monocyte chemoattractant
protein-1 in an ischemic stroke model (Villa et al. 2003). Moreover, EPO also diminishes
inflammation and glial activation in a model of brain inflammation (Shang et al. 2011).
These data collectively suggest that EPO act as a protective cytokine in inflammatory
pathologies of neurodegeneration, including AD.
The effect of immunomodulatory peptides on EPO expression in cultured human neurons,
microglia, astrocytes, and oligodendrocytes has also been investigated. EPO expression in
human astrocytes was reduced by pro-inflammatory cytokines including IL-1β, IL-6 and
TNF-α, whereas, EPOR expression was markedly increased in human neuronal cells by
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TNF-α (Nagai et al. 2001). EPOR and EPO expression may thus be regulated by proinflammatory cytokines in the CNS.
Cognitive Function

Author Manuscript

AD is the most common cause of senile dementia and is characterized by a progressive
decline in cognitive function. Behavioral tests commonly used in animal AD studies attempt
to mimic deficits in memory and cognition of AD patients. In a contextual fear-conditioning
test, EPO improves associative learning memory in aged transgenic AD mice (S. T. Lee et
al. 2012). In a step-down inhibitory avoidance test, which measures short-term retention of
an aversive stimulus, intraperitoneal EPO treatment restores Aβ42-induced loss of step-down
latency (Y. P. Li et al. 2015). Intranasal EPO alleviates place learning and spontaneous
alteration deficits in the Morris Water Maze, which is used to measure spatial and long-term
memory by recording escape latency, distance and velocity (Rodriguez Cruz et al. 2017).
EPO administration also prevents deficits in alternation behavior in Y-maze and novel object
recognition procedures in Aβ25–35 injected mice (Rodriguez Cruz et al. 2017; Maurice et al.
2013). Non-spatial long-term memory function deficits, tested by the passive avoidance
procedure, are observed in AD and stroke models, and these are improved by EPO treatment
(Esmaeili Tazangi et al. 2015; Sakanaka et al. 1998). Using place learning in water maze,
hippocampus-dependent spatial memory is improved by EPO (Maurice et al. 2013).
Similarly, bilateral injection of Aβ into the rat cortex leads to memory loss and synaptic
plasticity defect, which are recovered by EPO (Esmaeili Tazangi et al. 2015).

(III) Limitation of EPO as a CNS-penetrating drug
Author Manuscript
Author Manuscript

Though EPO and EPOR have a role as an “endogenous neuroprotective system” in the brain,
BBB penetration and negative hematopoietic effects are the two major challenges that have
to be addressed before EPO can be developed as a neurotherapeutic. EPO is a 30.4 kDa
polar macromolecule and is larger than the molecular weight cut-off for lipid mediated free
diffusion across the BBB (Pardridge 2005; Konofagou et al. 2012). The finding that the
EPOR is expressed at the brain capillaries suggested that peripheral EPO may cross the BBB
to produce therapeutic effects in the brain (Brines et al. 2000). Further, systemically
administered biotinylated-EPO was detected surrounding the brain capillaries, and this
transport of biotinylated-EPO was eliminated by co-administration of unlabeled EPO
(Brines et al. 2000). Based on these findings, it was suggested that EPO is transported across
the BBB via a specific receptor-mediated transport system, however, the origin of the biotin
label detected in these studies (biotin conjugated to EPO or free biotin) was not confirmed.
The presumption that EPO enters the CNS is also largely based on measurement of
systemically administered EPO in the cerebrospinal fluid (CSF) (Brettschneider et al. 2006).
It should be noted that movement from blood into the CSF is controlled by the blood-CSFbarrier, and all molecules present in the blood enter the CSF at a rate that is inversely related
to their molecular weight (Pardridge 2016). Follow-up brain uptake studies using
radiolabeled EPO in rodents and primates showed that the rate of EPO entry into the brain
was very slow and that EPO entry into the brain was via a non-specific mechanism (Boado
et al. 2010; Banks et al. 2004). Using the capillary depletion technique, which separates the
brain homogenate into vascular pellet and postvascular supernatant, the rate of EPO entry
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into the brain was found to be comparable to that of a marker of brain blood volume (human
IgG1) showing the limited transport of EPO across the BBB (Boado et al. 2010).

Author Manuscript

EPO is administered systemically or intranasally in experimental AD (Esmaeili Tazangi et
al. 2015; Maurice et al. 2013; S. T. Lee et al. 2012; Y. P. Li et al. 2015; Armand-Ugon et al.
2015; Samy et al. 2016; Arabpoor et al. 2012). Systemic routes, though less invasive than the
intracranial or intracerebroventricular routes used to bypass the BBB, require high dosage to
infiltrate the brain and therefore result in heightened peripheral toxicity risk. As a red blood
cell growth factor, high systemic EPO doses induce negative hematopoietic side effects
including increased hematocrit, arterial hypertension, cerebral convulsion,
thromboembolism, iron deficiency, and influenza-like syndrome (Lapchak 2010; Lundby et
al. 2007). Such hematopoietic side-effects associated with high systemic doses limit the
applicability of the systemic route of administration for EPO delivery for chronic diseases
like AD that require long term treatment.

Author Manuscript

EPO analogs with reduced erythropoietic activity and associated vascular complications are
currently under investigation (King et al. 2007). Asialo-EPO, which is produced by the
removal of sialic acid residues from EPO to yield a molecule with enhanced clearance has
no effect on erythropoiesis but exerts neuroprotective effects in animal models of neural
diseases (Erbayraktar et al. 2003; Mennini et al. 2006). Another non-erythropoietic EPO
derivative, carbamylated-EPO (CEPO), which is produced by the modification of lysine
residues to homocitrulline, produces its protective effects through the EPOR/β common
receptor, and not the classical EPOR. In an AD mouse model, CEPO treatment improved
memory and modulated the expression of molecules involved in neurotransmission.
However, compared to EPO, CEPO did not decrease Aβ plaque burden and soluble Aβ40
(Armand-Ugon et al. 2015). The CEPO-Fc variant, which is engineered to prolong the halflife of CEPO, was also found to be protective in a rodent AD model (Hooshmandi et al.
2018). Notably, these non-erythropoietic variants of EPO are also macromolecules with
limited BBB penetrability across the BBB, comparable to that of EPO (Torup and Leist
2006).

Author Manuscript

Another variant of EPO, neuro-EPO, which contains low sialic acid, has been designed.
Neuro-EPO is devoid of hematopoietic effects and is administered intranasally. Neuro-EPO
prevents oxidative damage, neuroinflammation, apoptosis and cognitive deficit in an AD
animal model (Rodriguez Cruz et al. 2017; Maurice et al. 2013). Even though intranasal
administration is advantageous over systemic administration with respect to systemic side
effects, the efficacy of intranasal drug delivery decreases as molecular weight and
hydrophilicity of the drug increase (Lu et al. 2014). Moreover, intranasal delivery relies on
widespread drug diffusion from the olfactory CSF to brain entry sites, and drug diffusion
decreases exponentially with distance (Lochhead and Thorne 2012; Pardridge 2012). Large
diffusion distances in human brains compared with smaller rodent brains may limit the
efficacy of the intranasal route of administration in humans. This is in contrast to the
transvascular route across the BBB that results in widespread drug delivery throughout the
brain because of the density and ubiquity of the cerebral vasculature (Pardridge 2005).
Hence, modifying EPO for direct and specific penetration of the BBB via the transvascular
route and minimal hematopoietic effects is needed for AD.
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(IV) BBB Receptor Mediated Transport of EPO
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Molecular Trojan horse (MTH) technology holds promise for efficiently transporting
neurotherapeutics across the BBB (Pardridge 2006, 2017). MTH technology harnesses
endogenous receptor mediated transcytosis (RMT) systems to ferry macromolecules into the
brain. For this, a fusion protein of the neurotherapeutic and a MTH, which is an antibody
against an endogenous receptor expressed on the luminal side of brain endothelial cells, is
engineered. Systemic injection of the neurotherapeutic-MTH complex triggers its binding to
the endogenous RMT receptor on the luminal side of the BBB, followed by subsequent
endocytosis and release of the complex on the abluminal side (Pardridge 2012, 2009). This
approach can therefore be used to shuttle therapeutic molecules across the BBB noninvasively to treat CNS pathology (Preston et al. 2014). The two widely studied MTH
vehicles are antibodies against the human insulin receptor and transferrin receptor (TfR)
(Jones and Shusta 2007; Pardridge 2006).
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The TfR system is responsible for transporting transferrin-bound iron from blood across the
brain endothelium into the brain parenchyma (Roberts et al. 1993; Jefferies et al. 1984;
Fishman et al. 1987). TfR is a type II transmembrane protein and is expressed at both the
luminal and abluminal surface of brain endothelial cells (Huwyler and Pardridge 1998).
There are two TfR isoforms, TfR1 and TfR2, and the primary TfR isoform expressed at the
BBB is TfR1 (J. Y. Li et al. 2001). Upon binding of the iron-transferrin complex on the
luminal surface, TfR enters the brain endothelial cells via endocytosis. Once inside the brain
endothelial cells, the remaining mechanism for iron entry into the brain is debatable. One
proposed mechanism is transport of the iron-transferrin-TfR complex from the luminal to
the abluminal membrane of brain endothelial cells followed by release of iron and
transferrin into the brain interstitium with subsequent reverse transcytosis of iron-free
transferrin into the blood; while another is dissociation of the iron from the transferrin-TfR
complex within the acidified endosomes in the brain endothelial cells and transcytosis of the
iron across the abluminal membrane to enter the brain (Roberts et al. 1993; H. J. Lee et al.
2000; Dautry-Varsat et al. 1983; Moos et al. 2007; Y. Zhang and Pardridge 2001).
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The common mechanism of transcytosis of varying MTHs across the abluminal membrane
is also debated, and it is clear that antibodies against the TfR may differ based on their
affinity for the TfR. Both high- and low-affinity, as well as monovalent and bivalent TfR
antibodies have been engineered, and these different antibodies for the same TfR may
warrant different success rates of entry into the brain parenchyma (Niewoehner et al. 2014;
Yu et al. 2011; Weber et al. 2018; Hultqvist et al. 2017; Chang et al. 2018). Some studies
suggest that TfR antibodies with high affinity can be trapped within the brain vasculature
due to their high affinity, which prevents their transportation across the abluminal side of
brain capillaries (Yu et al. 2011). Reducing the affinity of the TfR antibody to enhance RMT
across the BBB has been suggested as an alternative. It should however be noted that high
injection doses are needed to produce a therapeutic effect while using low-affinity TfR
antibodies, and such high doses result in effector function associated toxicity (acute-clinical
signs and reticulocyte suppression) (Couch et al. 2013). Low therapeutic doses of highaffinity TfR antibodies on the other hand do not produce an immune-response or reticulocyte
suppression (Pardridge et al. 2018). Overall, as the second most abundant protein on the
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brain endothelial cells compared to other RMT systems, TfR is considered an ideal
candidate for MTH drug-delivery of therapeutics across the BBB (Bien-Ly et al. 2014;
Pardridge 2015).
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To facilitate non-invasive transvascular EPO delivery into the brain, human EPO was reengineered as a TfR antibody-EPO fusion protein, designated as cTfRMAb-EPO (Figure 2).
The cTfRMAb domain of the fusion protein that enables BBB penetration is a rat/mouse
chimeric antibody that is specific to the mouse TfR and binds to the mouse TfR with high
affinity (KD of 2.6 ± 0.3 nM) in a bivalent configuration (Boado et al. 2009). The EPO
domain of the fusion protein binds to the mouse EPOR with an ED50 = 0.33 ± 0.04 nM to
produce neuroprotection in brain behind the intact BBB (Zhou et al. 2010). Intravenous
injection of radiolabeled cTfRMAb-EPO in mice results in a brain uptake of 2.0 ± 0.1%
injected dose/g of brain and ~70% of the fusion protein is transcytosed across the BBB into
the brain parenchyma measured using the capillary depletion technique (Zhou et al. 2010).
The plasma clearance of the cTfRMAb-EPO fusion protein is > 10-fold higher than that of
EPO due to the rapid peripheral TfR mediated clearance of the fusion protein (Kato et al.
1998). Such a pharmacokinetic profile of the cTfRMAb-EPO is desirable given that
increased plasma clearance lowers the potential for peripheral hematopoietic side effects
associated with the EPO domain of the fusion protein. In fact, desialylated variants of EPO
have a reduced half-life and increased clearance, and offer the possibility to uncouple
stimulation of erythropoiesis from tissue-protective effects of EPO (Erbayraktar et al. 2003;
Torup and Leist 2006).

Author Manuscript
Author Manuscript

Chronic 3 days a week intravenous treatment with the cTfRMAb-EPO fusion protein for 3
weeks offered neuroprotection in a mouse model of neural disease and resulted only in a
10% increase in hematocrit after 2 weeks of treatment with no further hematocrit increase
(Zhou et al. 2011). The dose of the cTfRMAb-EPO fusion protein in the aforementioned
study was 1mg/kg which is equivalent to an EPO dose of 200 μg/kg, since the cTfRMAbEPO fusion protein is 20% EPO based on the amino-acid sequence of the fusion protein.
Since the clearance of the cTfRMAb-EPO is > 10-fold faster than EPO, the equivalent EPO
dose is 20 μg/kg per dose or 60 μg/kg per week. This is lower than the doses of EPO that are
therapeutic in experimental models of AD (S. T. Lee et al. 2012; Armand-Ugon et al. 2015).
In a recent study, chronic treatment with the cTfRMAb-EPO fusion protein for 8 weeks
reduced Aβ pathology, microglial activation and synaptic loss in a transgenic mouse model
of AD. cTfRMAb-EPO further improved performance in the modified Y-maze, showing that
treatment with the BBB-penetrable EPO improved spatial memory in experimental AD
(Chang et al. 2018). High-affinity humanized TfR antibodies targeting the human TfR have
been engineered and their ability to act as efficient MTHs has been confirmed in primates
(Pardridge et al. 2018; Yu et al. 2014). Species-specific TfR antibody-EPO fusion proteins
can thus be engineered to translate these effects of the BBB-penetrable-EPO into other
species. Overall, engineering EPO variants that target the BBB TfR to enable BBB
penetration may provide a promising approach to further the development of EPO for
chronic neurodegenerative conditions including AD.
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Summary
EPO has evolved as a therapeutic agent for neurodegenerative conditions given its robust
non-hematopoietic neuroprotective effects. However, penetration of the BBB and negative
hematopoietic effects are the two major challenges for the development of EPO for chronic
neurodegenerative diseases like AD. Brain drug delivery strategies, such as the MTH
technology that harnesses endogenous RMT systems like the BBB TfR, hold promise for
efficiently transporting EPO across the BBB for AD, while increasing systemic clearance to
minimize hematopoietic side-effects.
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Fig 1. The neuroprotective effect of EPO in AD.

In experimental AD, EPO reduces Aβ toxicity, neuroinflammation and oxidative stress, and
enhances neurogenesis and neurotrophic factor expression.
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Fig 2. Schematic of routes of EPO brain delivery.
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Penetration of the BBB is a major challenge of EPO administration for CNS diseases
including AD. One hypothesis is the existence of EPOR on the luminal side of the brain
capillaries that is presumed to provide a route for circulating EPO to enter the brain. This
route of EPO entry remains debatable. In the absence of such a receptor, brain delivery of
EPO requires compromised BBB permeability. Alternatively, endogenous transferrin
receptors (TfR), which are receptor-mediated transcytosis systems, and are highly expressed
at the BBB can be harnessed to ferry EPO into the brain. A fusion protein of EPO and a
chimeric monoclonal antibody against TfR has been engineered and designated, cTfRMAbEPO. Upon binding to the BBB TfR, the cTfRMAb-EPO fusion protein is ferried into the
brain to enable EPO delivery into the brain across the BBB.
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